دانلود مقاله ISI انگلیسی شماره 48212
ترجمه فارسی عنوان مقاله

نظم فضایی و سرمایه گذاری مخاطره آمیز در صنعت بیوتکنولوژی آمریکا

عنوان انگلیسی
Spatial collocation and venture capital in the US biotechnology industry
کد مقاله سال انتشار تعداد صفحات مقاله انگلیسی
48212 2011 12 صفحه PDF
منبع

Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)

Journal : Research Policy, Volume 40, Issue 9, November 2011, Pages 1188–1199

ترجمه کلمات کلیدی
سرمایه گذاری مخاطره آمیز - بیوتکنولوژی - دامنه خوشه - سرریز دانش - اثرات خارجی شبکه - شرکت های بیوتکنولوژی اختصاصی - اثرات جانبی فضایی
کلمات کلیدی انگلیسی
C31; L25; O3; R12; L65Venture capital; Biotechnology; Cluster scope; Knowledge spillovers; Network externalities; Dedicated biotechnology firms; Spatial externalities
پیش نمایش مقاله
پیش نمایش مقاله  نظم فضایی و سرمایه گذاری مخاطره آمیز در صنعت بیوتکنولوژی آمریکا

چکیده انگلیسی

Biotechnology firms operate in a high-risk and high-reward environment and are in a constant race to secure venture capital (VC) funds. Previous contributions to the literature show that the VC firms tend to invest locally in order to monitor their investments and to provide operating assistance to their target firms. Further, biotechnology is a knowledge-based industry that tends to exhibit spatial clusters, and the firms in such industries may collocate to benefit from gaining access to local markets for specialized inputs (e.g., skilled researchers) and from local knowledge spillovers and network externalities. If such gains exist, we expect that the collocated firms should exhibit positively correlated performance, including in their ability to attract venture capital funds. The purpose of this paper is to empirically measure the strength and spatial extent of the relationships among the amount of funds raised by proximate biotechnology firms. We model these relationships with a spatial autoregression (SAR) model, and we control for characteristics of the biotechnology firms and the VC firms that provide their funds as well as site-specific factors. Based on our fitted SAR model, we find that the amount of venture capital raised by a particular biotechnology firm is significantly influenced by the number of VC firms and the VC funding levels raised by biotechnology firms located within a 10-mile radius, but these relationships are not statistically significant beyond this range.